comparemela.com

Latest Breaking News On - Vascular group - Page 1 : comparemela.com

Terumo : Appoints the Candidates for Directors

Terumo : Appoints the Candidates for Directors
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Sasakawa
Japan-general
Japan
Tokyo
Japanese
Shoji-hatano-yukiko-kuroda
Hikaru-samejima
Norimasa-kunimoto
Kazunori-hirose
Shinjiro-sato
Toshihiko-osada
Hidenori-nishi

Medtronic PLC Executive Vice President & President Cardiovascular Sean Salmon Sells 30,695 ...

Sean Salmon, Executive Vice President & President Cardiovascular at Medtronic PLC (NYSE:MDT), executed a sale of 30,695 shares in the company on February 21, 2024, according to a recent SEC Filing.

Fairly-valued
Medtronic-plc
Minimally-invasive-therapies-group
Restorative-therapies-group
Diabetes-group
Executive-vice-president
Vascular-group
Sean-salmon
Fairly-valued
Nsider-transaction
Insider-purchases

American Heart Month - WHIZ - Fox 5 / Marquee Broadcasting

American Heart Month - WHIZ - Fox 5 / Marquee Broadcasting
whiznews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from whiznews.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Mary-behanna
Vascular-group
Genesis-heart-vascular-institute
American-heart
Grant-chow
Genesis-heart

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood

New-jersey
United-states
State-of-new-jersey
Germany
Canada
New-york
Canadian
American
Kathleen-bloch
James-komsa
Irina-kulinets
Vincent-capponi

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data analysis completion expected before year-end.PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorptio

Canada
State-of-new-jersey
New-jersey
United-states
Germany
New-york
American
Canadian
Kathleen-bloch
Vincent-capponi
James-komsa
Phillip-chan

vimarsana © 2020. All Rights Reserved.